Different efficacy of propranolol in mice with oxygen-induced retinopathy: Could differential effects of propranolol be related to differences in mouse strains?

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 11, 2012, Pages 7421-7423

  Filippi, Luca ^a   Dal Monte, Massimo ^b   Bagnoli, Paola ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; CD31 ANTIGEN; NORADRENALIN; OXYGEN; PROPRANOLOL; PROTEIN P53; VASCULOTROPIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ANGIOGENESIS; DRUG EFFICACY; HUMAN; HYPOXIA; LETTER; NONHUMAN; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; RETINOPATHY; RETROLENTAL FIBROPLASIA; ANIMAL; NOTE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; HUMANS; PROPRANOLOL; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY;

EID: 84872034441     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10721     Document Type: Letter

References (25)

1. Chen J, Joyal JS, Hatton CJ, et al. Propranolol inhibition of β-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2012;53:2968-2977.
2. Praveen V, Vidavalur R, Rosenkrantz TS, Hussain N. Infantile hemangiomas and retinopathy of prematurity: possible association. Pediatrics. 2009;123:e484-e489.
3. Ristori C, Filippi L, Dal Monte M, et al. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Invest Ophthalmol Vis Sci. 2011;52:155-170.
4. Dal Monte M, Martini D, Latina V, Pavan B, Filippi L, Bagnoli P. Beta-adrenoreceptor (β-AR) agonism influences retinal responses to hypoxia in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2012;53:2181-2192.
5. Martini D, Dal Monte M, Ristori C, et al. Antiangiogenic effects of β2-adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. J Neurochem. 2011;119:1317-1329.
6. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol. 1996;114:1219-1228.
7. Bai Y, Ma JX, Guo J, et al. Müller cell-derived VEGF is a significant contributor to retinal neovascularization. J Pathol. 2009;219:446-454.
8. Yafai Y, Iandiev I, Wiedemann P, Reichenbach A, Eichler W. Retinal endothelial angiogenic activity: effects of hypoxia and glial (Müller) cells. Microcirculation. 2004;11:577-586.
9. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35: 101-111.
10. Aguilar E, Dorrell MI, Friedlander D, et al. Ocular models of angiogenesis. Methods Enzymol. 2008;444:115-158.
11. Stahl A, Connor KM, Sapieha P, et al. The mouse retina as an angiogenesis model. Invest Ophthalmol Vis Sci. 2010;51: 2813-2826.
12. Chan CK, Pham LN, Zhou J, Spee C, Ryan SJ, Hinton DR. Differential expression of pro-and antiangiogenic factors in mouse strain-dependent hypoxia-induced retinal neovascularization. Lab Invest. 2005;85:721-733.
13. Williams K, Tea M, Brereton H, Michael M, Coster D. Heritable influences in oxygen-induced retinopathy. Paper presented at: Oral Communication at the XX Biennial Meeting of the International Society for Eye Research; July 21-25, 2012; Berlin, Germany. Abstract O096.
14. Schimanski LA, Ali DW, Baker GB, Nguyen PV. Impaired hippocampal LTP in inbred mouse strains can be rescued by beta-adrenergic receptor activation. Eur J Neurosci. 2007;25: 1589-1598.
15. Ikeda S, Hawes, NL, Chang B, Avery CS, Smith, RS, Nishina PM. Severe ocular abnormalities in C57BL/6 but not in 129/Sv p53-deficient mice. Invest Ophthalmol Vis Sci. 1999;40:1874-1878.
16. Good WV, Hardy RJ, Dobson V, et al. Early Treatment for Retinopathy of Prematurity Cooperative Group. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics. 2005;116:15-23.
17. Good WV, Hardy RJ, Wallace DK, et al. β-Blocking and racial variation in the severity of retinopathy of prematurity. Arch Ophthalmol. 2012;130:117-118.
18. Bruns LA, Canter CE. Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure? Paediatr Drugs. 2002;4:771-778.
19. Fritz KI, Bhat AM. Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review. J Perinatol. 1998;18:38-44.
20. Wong KK, Potts JE, Etheridge SP, Sanatani S. Medications used to manage supraventricular tachycardia in the infant a North American survey. Pediatr Cardiol. 2006;27:199-203.
21. Smith C, Thomsett M, Choong C, Rodda C, McIntyre HD, Cotterill AM. Congenital thyrotoxicosis in premature infants. Clin Endocrinol (Oxf). 2001;54:371-376.
22. Mahmoud AB, Tantawy AE, Kouatli AA, Baslaim GM. Propranolol: a new indication for an old drug in preventing postoperative junctional ectopic tachycardia after surgical repair of tetralogy of Fallot. Interact Cardiovasc Thorac Surg. 2008;7:184-187.
23. Garin EH, Araya CE. Treatment of systemic hypertension in children and adolescents. Curr Opin Pediatr. 2009;21:600-604.
24. Filippi L, Cavallaro G, Fiorini P, et al. Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491. BMC Pediatr. 2010;10:83.
25. Preslan MW, Butler J. Regression pattern in retinopathy of prematurity. J Pediatr Ophthalmol Strabismus. 1994;31:172-176.